Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities (2023 - 2025)

CG Oncology (CGON) has disclosed Cash from Financing Activities for 3 consecutive years, with $99.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 55.66% year-over-year to $99.1 million, compared with a TTM value of $153.6 million through Dec 2025, down 75.55%, and an annual FY2025 reading of $153.6 million, down 75.55% over the prior year.
  • Cash from Financing Activities was $99.1 million for Q4 2025 at CG Oncology, up from $54.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $402.7 million in Q1 2024 and bottomed at -$15.2 million in Q2 2023.
  • Average Cash from Financing Activities over 3 years is $72.4 million, with a median of $1.3 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities skyrocketed 52735.03% in 2024, then crashed 840.0% in 2025.
  • Year by year, Cash from Financing Activities stood at -$2.9 million in 2023, then soared by 7814.57% to $223.4 million in 2024, then tumbled by 55.66% to $99.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CGON at $99.1 million in Q4 2025, $54.4 million in Q3 2025, and -$296000.0 in Q2 2025.